retatrutide for diabetes More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase ESC 2024: Retatrutide improves lipid

11 These measures included treatment satisfaction, treatment convenience, treatment flexibility, physical function, self-esteem, and work as compared to the insulin lispro group

Long-term extension studies provide helpful insights

That remains speculative until the data is published

The goal is minimizing that loss through adequate protein intake and resistance training

Then repeat the cycle

Clinical Evidence: Real Weight Loss Numbers from Trials The STEP trials, which tested semaglutide in adults with overweight or obesity, showed participants lost an average of 15% of body weight over 68 weeksroughly 35 pounds for someone weighing 230 pounds